

Medical Imaging Reagents Market Share is booming in next 10 years

PORTLAND, KY, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- Demand for medical imaging reagents is on the rise, owing to surge in prevalence of various chronic disorders such as cancer and cardiovascular disease, which require medical imaging for diagnosis, which, in turn, employee the use of medical imaging reagents across the globe. Furthermore, surge in geriatric population, which is more prone to chronic disorders is another major factor that fuels the market growth.



Medical Imaging Reagents Market 2030

According to the report, the global medical imaging reagents industry generated \$11.69 billion in 2019, and is expected to generate \$17.32 billion by 2027, growing at a CAGR of 5.0% from 2019 to 2027.

Drivers, restraints, and opportunities

Rise in prevalence of chronic diseases, surge in awareness for early disease diagnosis, and demand for diagnostic imaging procedures drive the growth of the global medical imaging reagents market. However, lack of access from underdeveloped countries and scarcity of imaging reagents hinder the market growth. On the other hand, increase in expenditure on healthcare and demand for effective procedures & safe medication present new opportunities in the coming years.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/1664

The contrast reagents segment to maintain its lead position during the forecast period

Based on class, the contrast reagents segment contributed to the largest market share in 2019, accounting for more than half of the global medical imaging reagents market, and is projected to maintain its lead position during the forecast period. This is attributed to rise in approvals for contrast reagents, surge in establishment of public & private diagnostic centers, and prevalence of cardiovascular diseases. However, the nuclear reagents segment is estimated to witness the highest CAGR of 6.4% from 2019 to 2027, owing to increase in application in research and development activities of cancer diagnosis.

The nanoparticles segment to maintain its leadership status by 2027

Based on technology, the nanoparticles segment held the highest market share, accounting for more than one-fourth of the global medical imaging reagents market in 2019, and is expected to maintain its leadership status throughout the forecast period. Moreover, this segment is projected to grow at the fastest CAGR of 6.8% during the forecast period. This is due to increase in utilization in detection of cancer tumors and improvement in specificity & sensitivity of scans obtained through MRI or CT. The report also provides a detailed analysis of segments including fluorescent dyes & probes, radiopharmaceuticals, fluorescent proteins, and quantum dots.

North America to maintain its highest contribution by 2027

Based on region, North America contributed to the highest share in terms of revenue with nearly two-fifths of the global medical imaging reagents market in 2019, and is expected to maintain its highest contribution by 2027. This is attributed to rise in prevalence of cardiovascular & neurological diseases and cancer, huge target population with higher health awareness, and availability of trained medical professionals. However, Asia-Pacific is expected to grow at the highest CAGR of 7.3% during the forecast period. This is due to increase in adoption of medical imaging reagents, rise in healthcare expenditure, and huge patient base suffering from chronic diseases such as cardiovascular diseases and cancer.

Inquiry for Buying@ https://www.alliedmarketresearch.com/purchase-enquiry/1664

Leading market players

Bayer AG
Bracco SpA
Cardinal Health
Eli Lilly and Company
General Electric Company (GE Healthcare)
Lantheus Holdings, Inc.
LI-COR Biosciences Inc.
Merck KGaA (Sigma-Aldrich)
PerkinElmer, Inc.
Thermo Fisher Scientific Inc.

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+15038946022 ext.
email us here
Visit us on social media:
Facebook
X
LinkedIn
YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/791653420

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.